Objectives: to investigate whether peripheral blood levels of matrix metalloproteinases (MMPs) 
Introduction
the main physiological regulators of the extracellular matrix. Secreted in a latent pro-enzyme form by a range of cell types, including inflammatory cells, The atherosclerotic plaque is a dynamic structure, fibroblasts and smooth muscle cells, they require acundergoing continuous remodelling of the extrativation by limited proteolysis. There is evidence linkcellular matrix upon which its structural integrity ing MMPs to disease states in which tissue degradation depends. Acute changes within the plaque are a preplays a key role, including aneurysmal disease, 8, 9 canlude to the onset of clinical ischaemic events. 1 If the cer, 10, 11 and arthritis. 12 Their role in pathological states plaque undergoes acute disruption such as rupture or has led to the development of specific inhibitors, some ulceration, exposure of highly thrombogenic material of which are currently involved in clinical trials. 13 in the plaque core leads to thrombus formation. SecInitial plaque disruption has been shown to occur ondary thrombo-embolism may then cause stroke.
predominantly in the shoulder of the plaque, an area There is considerable evidence to support the theory rich in macrophages. 14 The production of MMPs in that acute plaque changes immediately precede the this region has been shown to be significantly higher onset of clinical symptoms. Histological studies have than in other parts of the plaque. 15 MMP activity in shown that plaque rupture, 2 intra-plaque haemorrhage coronary plaques has been shown to correlate closely and overlying thrombus 3 are significantly more comwith the onset of unstable angina, and of particular mon in patients with recent symptoms compared to interest are the gelatinases, MMP-2 and MMP-9. 6 those without. Significant disease progression is three MMP-2 is constitutively expressed in vascular times more likely to be identified on Duplex ultrasound smooth muscle cells in normal arteries and plaques in patients immediately after an ischaemic event than exhibit increased levels of expression. Plaques prone in patients who have remained asymptomatic. 4 to acute disruption also exhibit induction and acRecent work suggests that each phase of the atherotivation of MMP-9 in smooth muscle cells and insclerotic process may be mediated by a series of enflammatory macrophages. More recently, the level of zymes called matrix metalloproteinases or MMPs, [5] [6] [7] MMP-9 has been shown to be four times higher in the most unstable plaques based on symptomatology, * Please address all correspondence to: I. M. Loftus, Lecturer, Deembolisation and histological features of plaque inpartment of Surgery, RKCSB, Leicester Royal Infirmary, PO Box 65, stability. 16 There are no systemic markers or in-most at risk of disruption towards which pharBlood sampling and immunoassay macotherapy could be targeted.
Reports have suggested that the levels of MMPs Blood samples were drawn from the peripheral vein of each patient 24 h preoperatively. For the preparation are elevated not only in affected tissue but also in peripheral blood in patients with cancer, arthritis and of plasma 2Na-EDTA (final 0.1%) was added to whole blood. Following centrifugation, plasma was siphoned more recently acute coronary syndromes. 17, 18 This raises the possibility that patients at risk of acute into freezing vials, snap frozen in liquid nitrogen and stored at −80°C. plaque disruption may have elevated blood levels of MMPs.
MMP and TIMP quantification was performed using ELISA techniques for MMP-1, MMP-2, MMP-3, MMPThe aim of this study was to investigate the plasma levels of the major MMP and TIMP (tissue inhibitor 9, TIMP-1, TIMP-2 and TIMP-1/MMP-1 complex using Biotrak assay systems (Amersham, Amersham, Bucks, of MMP) subtypes in patients undergoing carotid endarterectomy to ascertain any differences in those with U.K.), validated for use with human plasma. 17 These provide a specific and precise quantitative despontaneous particulate embolisation, probably the most sensitive indicator of plaque instability. 19 termination of enzyme levels and are based on a twosite ELISA sandwich format, employing two antibodies directed against different epitopes of the enzyme.
During the first incubation step, MMP present in Materials and Methods the tissue homogenate binds to a microtitre plate precoated with antibody. During the second incubation Seventy-five consecutive patients admitted for carotid step, detection antibody coated with horseradish perendarterectomy (CEA) into a single vascular surgical oxidase (HP) is added, which forms an immobilised unit were entered into this study. Local ethical com-complex. The amount of peroxidase bound to each well mittee approval was obtained for the procurement of is determined by the addition of tetramethylbenzidine specimens and all patients gave full informed consent (TMB). The reaction is stopped by the addition of an for the study. A clinical history was obtained from acid solution and the resultant colour measured at each patient, with particular care taken to establish 450 nm in a microtitre plate spectrophotometer. The the number and duration of ischaemic events. All concentration of enzyme is determined by inpatients underwent a thorough neurological ex-terpolation from a standard curve. amination. Focal cerebral ischaemic events were deThe MMP-2 and MMP-9 assays recognise free and fined as transient ischaemic attack, amaurosis fugax, TIMP complexed pro-enzyme only, showing no crosscentral retinal artery occlusion or cerebrovascular ac-reactivity with activated forms of the enzyme nor other cident. All patients were on long-term aspirin therapy MMPs. The MMP-1 and MMP-3 assays recognise total (75 or 150 mg daily) and underwent a pre-operative enzyme both active and latent, plus enzyme complexed Duplex ultrasound assessment of the carotid plaque with TIMPs. The TIMP-1/MMP-1 complex assay refor quantification of the degree of stenosis.
cognises activated MMP-1 that has subsequently been Preoperatively patients were monitored with trans-complexed with TIMP-1, but not free MMP-1 or TIMPcranial Doppler (TCD) for 30 min, plus intraoperatively 1.The TIMP-1 assay recognises all TIMP-1, both free during the dissection phase of the operation. This and complexed with MMPs, while the TIMP-2 assay aimed to identify those with ongoing particulate micro-detects all TIMP-2 except that bound to pro-MMP-2. embolisation, highly indicative of plaque instability. 19 Continuous TCD monitoring of the ipsilateral middle cerebral artery was performed using a SciMed PC Dop 842 TCD (SciMed, Bristol, U.K.). Signals were recorded onto digital audio-tape for off line analysis and inStatistical analysis terpretation of embolic signals as described previously. 20 For the purpose of this study, emboli were All results are expressed as median values and interquartile ranges. Risk factors were analysed using the only recorded if they occurred in the preoperative period or the dissection phase of the operation and, chi-squared test, whilst differences in MMP levels were analysed using the non-paired, non-parametric after internal carotid artery clamping, recording was discontinued. This was to ensure that all recorded Mann-Whitney U-test. Significance was assumed with a p value <0.05. Logistic regression analysis was peremboli represented spontaneous dislodgement of particulate matter from the plaque rather than air emboli formed using the SPSS 8.0 statistical package and the individual risk factors expressed as a relative risk. and/or thrombus relating to the surgical procedure. with no difference between the groups in the percentage stenosis. median concentration of 44 ng/ml (iqr 31-59 ng/ml). Figure 1 demonstrates the peripheral blood levels
The plasma levels of MMP-2 in both groups were of MMP-9 in patients with or without evidence of very similar (median concentration 921 ng/ml for no spontaneous particulate embolisation. The level of emboli vs. 991 ng/ml for those with emboli) and close MMP-9 detected on ELISA was significantly higher in to previously published levels for patients with corpatients with embolisation than those without (p= onary atherosclerosis.
0.03, Mann-Whitney U-test). In the non-embolising
The circulating levels of MMP-1, MMP-1/TIMP-1 group, the median MMP-9 level was 26 ng/ml (iqr complex and MMP-3 were very low, with no difference 19-40 ng/ml). This is very similar to the levels pre-between those patients who were embolising and those viously reported in normal volunteers. In the em-not embolising (Table 2) . bolising group the level was much higher, with a Whilst quite high concentrations of both TIMP-1 and TIMP-2 were detected in plasma of embolising and non-embolising patients, there were no significant differences between the groups in either inhibitor ( Table 2) .
Logistic regression analysis was performed to assess whether the plasma level of MMP-9 represented an independent predictor of embolisation. Taking all other atherosclerotic risk factors into account and the presence of neurological symptoms, plasma MMP-9 levels represented the only significant predictor of embolisation (p=0.05). A plasma MMP-9 level of greater than 30.2 ng/ml (the median value for the Fig. 1 . Graph demonstrating the significantly higher MMP-9 con-entire patient group) equated to a relative risk of centration in embolising patients compared to those without emboli (p=0.03). embolisation of 2.54 (Table 3) . Whilst the presence of symptoms and a history of ischaemic heart disease cause an increased MMP-2 and MMP-9 activity, 24 whilst further studies have shown that MMP-9 may increased the risk of embolisation, they failed to reach significance.
contribute to post-infarction oedema and haemorrhage. 25 More recently, MMP-2 and MMP-9 levels All patients made uneventful postoperative recoveries with no perioperative strokes or deaths.
have been demonstrated to increase very early within ischaemic basal ganglia of non-human primates in parallel with evidence of neurone injury. 26 In humans the level of cerebral MMP-9 has been shown to be Discussion high in association with an inflammatory infiltration predominantly of leukocytes in patients who died The present study showed increased plasma levels shortly after a stroke.
27
of MMP-9 in those patients with significant carotid Increased cerebral levels of MMP-9 may therefore stenoses undergoing carotid endarterectomy in whom contribute to early disruption of the microvascular spontaneous particulate embolisation was detected. basal lamina and accentuate neuronal injury. The celluThere were no differences in the circulating levels of lar source of cerebral MMPs remains unclear but focal other MMPs or their naturally occurring inhibitors, cerebral ischaemia may influence plasma MMP levels TIMPs-1 and -2. This suggests a shift in the balance and vice versa. of circulating proteolytic enzymes towards proteolysis,
Ji Hoe Heo and colleagues demonstrated a transient a process that is usually tightly controlled.
rise in circulating MMP-9 levels in a rat model of This may represent one of two phenomena. Firstly, middle cerebral artery occlusion. 26 However, there are it may reflect a systemic manifestation of the localised no previous reports linking plasma MMP levels with increase in MMP-9 levels and activity previously dem-markers of plaque instability. Circulating levels of both onstrated within unstable plaques, occurring in tan-MMP-2 and MMP-9 have been shown to increase in dem with intense localised inflammation and tissue patients with acute coronary syndromes. Kai et al. degradation. MMPs are now recognised to play a key measured plasma MMP levels in 33 patients with acute role in many aspects of the atherosclerotic process, coronary syndromes, 17 patients with stable angina but particularly the onset of instability and plaque and 17 normal controls. 18 Early increases in circulating rupture. The intraplaque level, activity and expression levels of both MMP-2 and MMP-9 were demonstrated of MMP-9 has been shown to be significantly higher in patients with acute coronary syndromes, higher in the most unstable plaques based on patient symp-than both normal controls and those with stable antomatology, spontaneous embolisation and histo-gina. These results support those of the current paper, logical features on instability. 16 There may be an though we recognise the possibility of a chance finding increased release of the enzyme into the circulation and the need for larger scale studies. from the plaque itself, or by circulating macrophages Further investigations are required to address the involved in the inflammatory response promoting cellular source of the increased circulating MMP-9 plaque degradation. In acute coronary syndromes, levels observed in embolising patients. However, it for example, monocytes in the systemic circulation may represent a useful marker of plaque instability or undergo activation and may represent a source of the general level of atherosclerosis-related inenzyme. 21 flammation and perhas identify a cohort of patients The increase may on the other hand represent a who warrant urgent intervention. marker of end organ ischaemia in the form of thromboembolic cerebral damage. CT scans were not performed in this study to look specifically for evidence of infarction because previous studies of particulate Acknowledgements embolisation have found that CT is unhelpful in this age may be psychometric testing and previous studies have shown a clear link between particulate embolisation and a deterioration in psychological scoring.
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